OICR fund provides $1.5 million to Flourinov

Guest Contributor
July 5, 2012

The Ontario Institute for Cancer Research (OICR) is investing $1.5 million over three years in Toronto-based Flourinov Pharma Inc to further develop a drug to treat multiple myeloma and some forms of non-Hodgkin's lymphoma. The drug — FV162 — is a highly potent, orally-delivered small molecule proteasome inhibitor which displays significant advantages over existing drugs. The funding comes from OICR's Intellectual Property Development and Commercialization Fund and will assist the privately held Flourinov in meeting the preclinical requirements of Health Canada and the US FDA. Current proteasome inhibitor-based treatment is toxic and requires intravenous delivery....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.